Dianna Clyne, MD
Psychiatry · Lincoln, NENPI 1114035938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,887 of the $18,949 with a category attached, or 78.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $6,580 and has fallen 64.4% since, to $2,345 in 2025. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 981 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$4K
- AbbVie$4K
- Otsuka America Pharmaceutical, Inc.$2K
- Lundbeck LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- plus $6K from 28 others
What the payments were for
- Food & beverage$14,88779%
- Education$1751%
- Other$3,88821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 3 | $3,901 |
| AbbVie(2 entities) | 272 | $3,653 |
| Otsuka America Pharmaceutical, Inc. | 114 | $1,636 |
| Lundbeck LLC | 98 | $1,320 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,204 |
| Alkermes, Inc. | 61 | $1,023 |
| Teva Pharmaceuticals USA, Inc. | 37 | $744 |
| Johnson & Johnson | 43 | $694 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $531 |
| Jazz Pharmaceuticals Inc. | 27 | $508 |
| Harmony Biosciences LLC | 27 | $497 |
| Neurocrine Biosciences, Inc. | 25 | $422 |
| Sunovion Pharmaceuticals Inc. | 41 | $392 |
| Axsome Therapeutics, Inc. | 18 | $335 |
| Supernus Pharmaceuticals, Inc. | 14 | $314 |
| Bausch Health US, LLC | 18 | $307 |
| Vanda Pharmaceuticals Inc. | 12 | $284 |
| Idorsia Pharmaceuticals US Inc | 13 | $238 |
| E.r. Squibb & Sons, L.L.C. | 5 | $123 |
| Ironshore Pharmaceuticals Inc. | 7 | $117 |
| Merck | 7 | $110 |
| Tris Pharma Inc | 4 | $85 |
| Neos Therapeutics, LP | 4 | $77 |
| Avanir Pharmaceuticals, Inc. | 4 | $61 |
| Acadia Pharmaceuticals Inc | 3 | $55 |
| Noven Therapeutics, LLC | 3 | $54 |
| Indivior Inc. | 3 | $50 |
| Biogen | 2 | $46 |
| Eisai Inc. | 2 | $38 |
| Itamar Medical Inc | 1 | $36 |
| Livanova USA, Inc. | 2 | $32 |
| Brainsway USA Inc | 1 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$3,853
- INVEGA SUSTENNA$124
- VRAYLAR$104
How this compares
$18,949 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 119 | $165,391 |
| VraylarCariprazine Hcl | 33 | $52,714 |
| AristadaAripiprazole Lauroxil | 13 | $29,658 |
| TrintellixVortioxetine Hydrobromide | 37 | $25,209 |
| BelsomraSuvorexant | 35 | $15,269 |
| Clozapine OdtClozapine | 25 | $11,754 |
| Aripiprazole | 77 | $7,837 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 63 | $5,080 |
| Lurasidone Hcl | 16 | $4,743 |
| Clozapine | 106 | $4,550 |
| Quetiapine Fumarate | 207 | $4,449 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,236 |
| Lisdexamfetamine Dimesylate | 24 | $3,723 |
| Buspirone Hcl | 225 | $3,394 |
| Duloxetine Hcl | 154 | $3,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $694 | $165,391119 claims |
| AbbVieVraylar | $3,653 | $52,71433 claims |
| Alkermes, Inc.Aristada | $1,023 | $29,65813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $531 | $29,44548 claims |
| MerckBelsomra | $110 | $15,26935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Lincoln
- Walter DuffyLincoln$46K
- Jeffrey CoffmanLincoln$18K
- Kelli BremerLincoln$13K
- Rajeev ChaturvediLincoln$6K
- Danielle BudaLincoln$5K
- Ryan SantinLincoln$2K
- Andi NgoLincoln$1K
- Jessica BuettnerLincoln$1K
- Sanat RoyLincoln$794
- William MichaelLincoln$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.